UTHR's competitive advantages, including high returns on capital and successfully recycling of profits, support a bullish outlook. United Therapeutics' Q3 FY '24 earnings showed strong growth across major product lines, with Tyvaso, Orenitram, and Unituxin all posting significant YoY increases. My numbers project a 40% growth in earnings power for the business over the coming 2-3 years.
Despite legal challenges and exclusivity risks, United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. UTHR is innovating in organ transplantation and bioengineered organs, including xenotransplantation and ex vivo lung perfusion, which could revolutionize the market. Legal battles, particularly with Liquidia, threaten United Therapeutics' intellectual ...
United Therapeutics Corporation's stock has surged over 300% since my 2020 “Buy” rating, driven by strong sales of Tyvaso DPI and other PAH treatments. Despite facing generic competition, United has maintained resilience, leveraging strategic litigation and innovative product development to protect and grow its revenue streams. United's future growth hinges on expanding Tyvaso DPI's market and ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company's operations during a fireside chat session at the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. Th...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023. "I'm proud of the cl...
SILVER SPRING, Md. & JACKSONVILLE, Fla.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and its subsidiary Lung Bioengineering Inc. (LBE) announced that the 500th lung transplant utilizing LBE's centralized ex vivo lung perfusion (EVLP) service was completed last month. These 500 transplants were the result of evaluating over 800 donated lungs usi...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.